ℹ️
🇬🇧
Search
Search for publications relevant for "2nd malignancy risk"
2nd malignancy risk
Publication
Class
Person
Publication
Programmes
Export current view
publication
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
2015 |
Third Faculty of Medicine
